Contractor shall provide for a predictive bartlett esophagus assay pbea which will identify the probability that a patient will develop esophageal cancer over a 5 year period.
Ended Awarded Last action
- Contract number
- 36C26123N0593
- Awardee
-
Castle Biosciences, Inc. UEI JMKGWGQLA7X7
- Awarding agency
-
Veterans Integrated Service Network 21
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $2,500
Award facts
- Contract value 100% obligated
- $2,500.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541380 Testing Laboratories and Services
- PSC
- Q301 Reference Laboratory Testing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Palo Alto, CA 94304, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$10,000 | |
| Original award | $12,500 |
About this award
Castle Biosciences, Inc. was awarded a $2,500 firm fixed-price delivery order by Veterans Integrated Service Network 21 (VISN 21), a civilian agency within the Department of Veterans Affairs, to provide the Predictive Bartlett Esophagus Assay (PBEA). The PBEA is an advanced diagnostic test designed to identify the probability that a patient will develop esophageal cancer within a five-year period, supporting the VA's cancer risk assessment and screening initiatives for veterans. The contract was awarded on September 15, 2023, with an ultimate completion date of September 14, 2024. The place of performance is located in Palo Alto, California.
This delivery order is part of Castle Biosciences' broader portfolio of federal contracts with the VA, which includes a larger $3 million Indefinite Delivery Vehicle for the PBEA extending through September 2025. Castle Biosciences, a diagnostic testing company specializing in genomic profiling and cancer risk assessment, provides sophisticated molecular testing services to support VA healthcare delivery across multiple Veterans Integrated Service Networks. The company's federal contract work encompasses both the PBEA for esophageal cancer screening and the DecisionDx-Melanoma test, which utilizes gene expression profiling to predict melanoma recurrence risk. No set-aside designation was applied to this award.
Quick answers
Who was awarded contract 36C26123N0593?
36C26123N0593 was awarded to Castle Biosciences, Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on September 15, 2023.
How much is contract 36C26123N0593 worth?
The government has obligated $2,500 on 36C26123N0593.
Is contract 36C26123N0593 an order under another contract?
Yes. 36C26123N0593 is a delivery order under 36C26121D0108, an indefinite delivery contract.
Was contract 36C26123N0593 competed?
The extent of competition for 36C26123N0593 was not competed under sap.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award